CN103980361B - 抗体 - Google Patents

抗体 Download PDF

Info

Publication number
CN103980361B
CN103980361B CN201410209919.1A CN201410209919A CN103980361B CN 103980361 B CN103980361 B CN 103980361B CN 201410209919 A CN201410209919 A CN 201410209919A CN 103980361 B CN103980361 B CN 103980361B
Authority
CN
China
Prior art keywords
cell
antibody
seq
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410209919.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103980361A (zh
Inventor
林荣华
张重男
陈佩君
黄久珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abgenomics Corp
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103980361(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of CN103980361A publication Critical patent/CN103980361A/zh
Application granted granted Critical
Publication of CN103980361B publication Critical patent/CN103980361B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201410209919.1A 2004-05-10 2005-05-10 抗体 Expired - Fee Related CN103980361B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
US60/569,892 2004-05-10
CN200580023307.2A CN1984680B (zh) 2004-05-10 2005-05-10 抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200580023307.2A Division CN1984680B (zh) 2004-05-10 2005-05-10 抗体

Publications (2)

Publication Number Publication Date
CN103980361A CN103980361A (zh) 2014-08-13
CN103980361B true CN103980361B (zh) 2017-06-23

Family

ID=35394680

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410209919.1A Expired - Fee Related CN103980361B (zh) 2004-05-10 2005-05-10 抗体
CN200580023307.2A Expired - Lifetime CN1984680B (zh) 2004-05-10 2005-05-10 抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200580023307.2A Expired - Lifetime CN1984680B (zh) 2004-05-10 2005-05-10 抗体

Country Status (27)

Country Link
US (8) US7604800B2 (https=)
EP (3) EP1765396B1 (https=)
JP (4) JP5623690B2 (https=)
KR (1) KR101256400B1 (https=)
CN (2) CN103980361B (https=)
AR (1) AR048781A1 (https=)
AU (1) AU2005244072C1 (https=)
BR (1) BRPI0510567B8 (https=)
CA (3) CA2812040C (https=)
DK (1) DK1765396T3 (https=)
EC (1) ECSP067056A (https=)
EG (1) EG26781A (https=)
ES (3) ES2598034T3 (https=)
IL (3) IL178838A (https=)
MX (1) MXPA06012986A (https=)
MY (1) MY148646A (https=)
NO (1) NO341844B1 (https=)
NZ (3) NZ578647A (https=)
PH (1) PH12015500247A1 (https=)
PL (1) PL1765396T3 (https=)
PT (1) PT1765396E (https=)
RU (1) RU2482131C2 (https=)
SG (2) SG187443A1 (https=)
TW (2) TWI402274B (https=)
UA (1) UA100356C2 (https=)
UY (1) UY28886A1 (https=)
WO (1) WO2005110475A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) * 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
JP5773352B2 (ja) * 2008-10-28 2015-09-02 塩野義製薬株式会社 抗ｍｕｃ１抗体
TWI496295B (zh) * 2008-10-31 2015-08-11 Semiconductor Energy Lab 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2473531A4 (en) * 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
CA2803937A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital Reagents and methods for diagnosing conditions associated with hydroxylated hif 1-a
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
MX358447B (es) * 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
CA2850885A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI660972B (zh) * 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
EP3334453A4 (en) * 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
SG11201805557SA (en) * 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
EP3568159A4 (en) * 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CN118949063A (zh) * 2020-01-22 2024-11-15 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2023091958A1 (en) * 2021-11-17 2023-05-25 Altrubio Inc. Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers
TW202540180A (zh) * 2023-11-17 2025-10-16 美商美國全心醫藥生技股份有限公司 抗psgl-1抗體及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333123A (zh) * 2000-07-11 2002-01-30 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
CN1342085A (zh) * 1998-10-30 2002-03-27 遗传研究所有限公司 通过p－选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化
CN1473052A (zh) * 2001-08-03 2004-02-04 ̨ҽ����Ƽ��ɷ����޹�˾ P-选择素糖蛋白配体1的调节剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ATE179210T1 (de) * 1992-03-17 1999-05-15 Novartis Erfind Verwalt Gmbh Gentechnologisch hergestellte antikörper
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
NZ261991A (en) 1993-01-25 1998-04-27 Dana Farber Cancer Inst Inc Chimeric l and p selectin made by exchange of domains, uses thereof
CZ287295A3 (en) * 1993-05-05 1996-05-15 Cytel Corp Antibodies against p-selectin, method of detecting p-selectin, preparation processes of medicaments, pharmaceutical preparations, nucleic acids, cell lines and their use
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
EP0850243B1 (en) 1995-08-03 2003-10-08 Board Of Regents Of The University Of Oklahoma o-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
ATE321570T1 (de) * 2000-05-19 2006-04-15 Blood Res Center Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1342085A (zh) * 1998-10-30 2002-03-27 遗传研究所有限公司 通过p－选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化
CN1333123A (zh) * 2000-07-11 2002-01-30 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
CN1473052A (zh) * 2001-08-03 2004-02-04 ̨ҽ����Ƽ��ɷ����޹�˾ P-选择素糖蛋白配体1的调节剂

Also Published As

Publication number Publication date
CA2907141C (en) 2016-05-31
DK1765396T3 (en) 2014-02-24
IL178838A (en) 2017-08-31
PT1765396E (pt) 2014-02-25
ES2448468T3 (es) 2014-03-14
US20090191204A1 (en) 2009-07-30
JP2014094010A (ja) 2014-05-22
IL178838A0 (en) 2007-03-08
EP2377889A3 (en) 2012-03-28
EP1765396B1 (en) 2013-11-20
IL228033A0 (en) 2013-09-30
KR20070020048A (ko) 2007-02-16
MXPA06012986A (es) 2007-02-12
AU2005244072C1 (en) 2012-09-20
EP2377890A3 (en) 2011-12-28
ECSP067056A (es) 2007-01-26
CA2812040C (en) 2016-05-03
BRPI0510567B8 (pt) 2021-05-25
ES2598034T3 (es) 2017-01-24
AR048781A1 (es) 2006-05-24
US20090198044A1 (en) 2009-08-06
KR101256400B1 (ko) 2013-04-26
PH12015500247A1 (en) 2015-12-14
CA2812040A1 (en) 2005-11-24
NZ590690A (en) 2012-10-26
PL1765396T3 (pl) 2014-07-31
US20130101587A1 (en) 2013-04-25
US9631019B2 (en) 2017-04-25
US20170190782A1 (en) 2017-07-06
US8287871B2 (en) 2012-10-16
US20150183870A1 (en) 2015-07-02
US8663641B2 (en) 2014-03-04
US20130102762A1 (en) 2013-04-25
SG10201606541UA (en) 2016-09-29
IL228032A0 (en) 2013-09-30
NO341844B1 (no) 2018-02-05
BRPI0510567B1 (pt) 2018-11-13
CA2566305C (en) 2014-10-14
JP2007536933A (ja) 2007-12-20
US20110172397A1 (en) 2011-07-14
CA2907141A1 (en) 2005-11-24
EP2377889B1 (en) 2016-07-13
NZ551626A (en) 2010-03-26
WO2005110475A2 (en) 2005-11-24
UY28886A1 (es) 2005-12-30
TWI402274B (zh) 2013-07-21
MY148646A (en) 2013-05-15
US20050266003A1 (en) 2005-12-01
EP1765396A4 (en) 2008-07-02
WO2005110475A3 (en) 2006-02-23
HK1102760A1 (en) 2007-12-07
CN1984680A (zh) 2007-06-20
TWI448474B (zh) 2014-08-11
JP2014223084A (ja) 2014-12-04
JP2011200247A (ja) 2011-10-13
NZ578647A (en) 2012-04-27
US10030075B2 (en) 2018-07-24
AU2005244072A1 (en) 2005-11-24
EP1765396A2 (en) 2007-03-28
BRPI0510567A (pt) 2007-11-20
EP2377890A2 (en) 2011-10-19
RU2482131C2 (ru) 2013-05-20
US8361472B2 (en) 2013-01-29
CA2566305A1 (en) 2005-11-24
UA100356C2 (ru) 2012-12-25
TW201313740A (zh) 2013-04-01
EP2377890B1 (en) 2016-08-10
TW200536860A (en) 2005-11-16
EG26781A (en) 2014-09-07
SG187443A1 (en) 2013-02-28
ES2602633T3 (es) 2017-02-21
US7604800B2 (en) 2009-10-20
US8828397B2 (en) 2014-09-09
AU2005244072B2 (en) 2012-05-31
CN103980361A (zh) 2014-08-13
NO20065542L (no) 2007-01-31
EP2377889A2 (en) 2011-10-19
JP5623690B2 (ja) 2014-11-12
CN1984680B (zh) 2014-11-05
RU2006143686A (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
CN103980361B (zh) 抗体
US11365255B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP4764627B2 (ja) 新生物疾患又は免疫不全を処置するためのヒト化免疫調節性モノクローナル抗体
KR101276596B1 (ko) 면역억제 특성을 가진 인간화 항-ｃｄ4 항체
WO2020043188A1 (zh) 抗cd47抗体及其应用
JP2015091820A (ja) 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質
CN105936648A (zh) Cd28结合为单价的组合物及使用方法
TW200927760A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
US20220332829A1 (en) Anti-b7-h3 antibody and application thereof
CN106061999A (zh) Il‑21抗体
CN102369219A (zh) 针对人tweak的抗体及其应用
CN113348182B (zh) Lag-3抗体及其医药用途
WO2023143534A1 (zh) 一种特异性识别4-1bb的抗体、其制备方法及其用途
WO2023178645A1 (zh) 靶向cd3的抗体及其应用
RU2696202C1 (ru) Гуманизация антител кролика с использованием универсального каркаса антитела
RU2567006C2 (ru) Гуманизация антител кролика с использованием универсального каркаса антитела
RU2652907C2 (ru) Гуманизация антител кролика с использованием универсального каркаса антитела
CN120112548A (zh) 靶向cd19和cd22的双特异性嵌合抗原受体
HK40051455A (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
HK1184168B (en) Antagonist anti-il-7 receptor antibodies and methods
HK1184168A1 (zh) 拮抗性抗il-7受体抗体及方法
HK1088337B (en) Humanized anti-cd4 antibody with immunosuppressive properties

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170623

Termination date: 20190510